# Clinical trials recruiting in Mississippi: 393 (2026)

Updated November 19, 2026.

ClinicalTrials.gov lists 393 trials recruiting or not yet recruiting with a site in Mississippi, as read on November 19, 2026.

## The full list

Clinical trials recruiting in Mississippi: 393 rows for $19.65, recruiting or not yet recruiting on ClinicalTrials.gov as read on November 19, 2026. Columns: NCT ID, Title, Sponsor, Sponsor class, Phase, Status, Conditions, Condition groups (MeSH), Interventions, Start date, First posted, Last update posted, Enrollment, Location countries, Read on, Source. The new rows each week by email, about 7 rows a month: $19 a month. Pay by card with no account. Prices exclude VAT. CSV and Excel files with the columns this page does not show (sponsor class, condition groups (MeSH), interventions, start date, last update posted and location countries), which open on your screen as soon as the payment clears and come by email. The rows on this page are a sample.

Buy: https://specstream.ai/data/clinical-trials/recruiting/state/mississippi

SpecStream is the live web data engine for teams and agents. It reads ClinicalTrials.gov each morning, and this page is that reading. Ask for the sponsors, conditions, phases or places you follow and each new or changed trial arrives in your sheet, CRM, Slack or agent with the sponsor, phase, status and sites.

- Trials: 393
- Recruiting or not yet: 393
- Read on: November 19, 2026

## Trials

The 25 newest of 393, each linked to its ClinicalTrials.gov record. The full list holds every one.

| First posted | NCT ID | Title | Sponsor | Phase | Status | Conditions | Enrollment | Source |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| November 9, 2026 | NCT07923981 | A Study to Assess the Safety of Marstacimab and How Well it Works in People With Mild to Moderate Hemophilia A or B Without Inhibitors | Pfizer | Phase 3 | Recruiting | Hemophilia A or B | 95 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07923981) |
| October 28, 2026 | NCT07900633 | A Study of Eloralintide (LY3841136) in Participants With Obesity or Overweight, Type 2 Diabetes, and Increased Cardiovascular Risk | Eli Lilly and Company | Phase 3 | Not yet recruiting | Obesity, Overweight, Cardiovascular Diseases, Diabetes Mellitus, Type 2 | 3,000 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07900633) |
| October 19, 2026 | NCT07881432 | A Study of EloraTZP in Adult Participants With Obesity Without Type 2 Diabetes | Eli Lilly and Company | Phase 3 | Not yet recruiting | Obesity | 2,115 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07881432) |
| October 9, 2026 | NCT07868939 | Oral VK2735 for Weight Management in Adults With Type 2 Diabetes Mellitus Phase 3 (SUNRISE 2) | Viking Therapeutics, Inc. | Phase 3 | Recruiting | Weight Loss | 560 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07868939) |
| October 9, 2026 | NCT07868835 | Oral VK2735 for Weight Management Phase 3 (SUNRISE 1) | Viking Therapeutics, Inc. | Phase 3 | Recruiting | Weight Loss | 560 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07868835) |
| October 9, 2026 | NCT07867080 | A Phase 3 Trial for Intravitreal Injection of 4D-150 in Adults With Diabetic Macular Edema (DME). | 4D Molecular Therapeutics | Phase 3 | Recruiting | Diabetic Macular Edema (DME) | 514 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07867080) |
| September 29, 2026 | NCT07845500 | A Study to Learn About Switching to a Monthly Study Medicine Called Berobenatide (PF-08653944) to Help Keep Weight Off in People With... | Pfizer | Phase 3 | Recruiting | Obesity, Overweight and/or Obesity, Overweight, Treatment Of Obesity | 660 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07845500) |
| September 29, 2026 | NCT07845487 | A Trial to Investigate PALI-2108 Versus Placebo in Participants With Moderately to Severely Active Ulcerative Colitis | Sponsor not shown (see the record) | Phase 2 | Recruiting | Ulcerative Colitis (UC), Severe Ulcerative Colitis, Moderate Ulcerative Colitis | 204 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07845487) |
| September 24, 2026 | NCT07840157 | A Mixed-Methods Exploratory Pilot Study of the Investigational MYNERVA Leia Sensory Prosthesis in U.S. Adults With Peripheral Neuropathy | Mynerva Inc. | Not applicable | Not yet recruiting | Peripheral Neuropathy | 100 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07840157) |
| September 18, 2026 | NCT07828613 | Accelerated Flap Coverage Versus Standard Timing in the Treatment of Severe Lower Extremity Musculoskeletal Injuries | Johns Hopkins University | Not applicable | Not yet recruiting | Open Tibia Fracture, Open Dislocation of Ankle, Extremity Fracture Lower, Extremity Injuries Lower | 356 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07828613) |
| September 4, 2026 | NCT07805707 | A Study on the Efficacy of a Vaccine Against Influenza in Adults ≥65 Years of Age | GlaxoSmithKline | Phase 3 | Recruiting | Influenza, Human | 54,000 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07805707) |
| August 31, 2026 | NCT07795814 | A Study of EDG-15400 in Adults With Heart Failure With Preserved Ejection Fraction (EQUINOX-HFpEF) | Edgewise Therapeutics, Inc. | Phase 2 | Recruiting | Heart Failure With Preserved Ejection Fraction | 90 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07795814) |
| August 25, 2026 | NCT07784270 | A Study to Evaluate Effect of AZD6234 in Adult Participants With Type 2 Diabetes Mellitus and Obesity or Overweight | AstraZeneca | Phase 3 | Recruiting | Obesity or Overweight, Diabetes Mellitus, Type 2 | 1,500 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07784270) |
| August 25, 2026 | NCT07783802 | A Study of Clazakizumab (LY5724886) in Adults With Elevated hsCRP and at Increased Risk for Cardiovascular Event | Eli Lilly and Company | Phase 2 | Recruiting | Atherosclerosis, Cardiovascular Disease, Obesity, Hypertension, Diabetes Mellitus, Type 2, Renal Insufficiency, Chronic | 120 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07783802) |
| August 20, 2026 | NCT07775495 | Observational Study of Decentralized Urine Optical Interaction Patterns Associated With Environmental Microplastic and Nanoplastic Exposure | Ecotera Health LLC | Observational | Recruiting | Healthy Adult Participants | 15 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07775495) |
| August 18, 2026 | NCT07769502 | A Study to Assess Adverse Events and Change in Disease Activity With Treatment Combinations With Telisotuzumab Adizutecan in Adults... | AbbVie | Phase 2 | Recruiting | Pancreatobiliary Cancers, Pancreatic Ductal Adenocarcinoma | 168 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07769502) |
| August 10, 2026 | NCT07754461 | A Study to Test Whether Survodutide Helps People With Type 2 Diabetes Control Their Blood Sugar | Boehringer Ingelheim | Phase 3 | Recruiting | Type 2 Diabetes | 600 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07754461) |
| August 10, 2026 | NCT07753993 | A Study to Investigate Outcomes With Elecoglipron Compared With Placebo in Adult Participants With Chronic Kidney Disease. | AstraZeneca | Phase 3 | Recruiting | Chronic Kidney Disease | 7,000 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07753993) |
| August 7, 2026 | NCT07752979 | Safety and Efficacy of ABBV-295 in Adults With Obesity or Overweight With Weight-Related Comorbidities | AbbVie | Phase 2 | Recruiting | Obesity, Overweight | 360 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07752979) |
| August 4, 2026 | NCT07745894 | VWCR to Improve Cardiovascular Health and Outcomes Among Cardiac Patients: A Multicenter Randomized Clinical Trial Protocol (Destination... | Mayo Clinic | Not applicable | Not yet recruiting | Heart Diseases | 150 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07745894) |
| August 3, 2026 | NCT07743463 | A Study of Once-daily Oral ASC30 to Evaluate the Efficacy and Safety in Adult Participants With Obesity or Overweight With Weight-Related... | Ascletis Pharma (China) Co., Limited | Phase 3 | Recruiting | Obesity, Overweight, Chronic Weight Management | 3,003 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07743463) |
| August 3, 2026 | NCT07743450 | A Study of Once-daily Oral ASC30 to Evaluate the Efficacy and Safety in Adult Participants With Obesity or Overweight With Type 2 Diabetes | Ascletis Pharma (China) Co., Limited | Phase 3 | Recruiting | Obesity, Overweight, Chronic Weight Management, Type 2 Diabetes Mellitus | 1,560 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07743450) |
| July 30, 2026 | NCT07736768 | Vitamin A Supplementation and Breast Milk Vitamin A Levels in Mothers of Preterm Infants | University of Mississippi Medical Center | Not applicable | Not yet recruiting | Premature, Preterm Infant Health, Vitamin A Deficiency, Human Milk, Breastfeeding | 20 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07736768) |
| July 29, 2026 | NCT07734844 | A Study to Evaluate the Efficacy and Safety of Tabirafusp Tedromer Compared to Aflibercept in Participants With DME - ALTO | Kodiak Sciences Inc | Phase 3 | Recruiting | Diabetic Macular Edema (DME) | 910 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07734844) |
| July 29, 2026 | NCT07734064 | A Study About the Safety of a Single ASP2020 Eye Injection and if it Helps People With Vision Loss From Stargardt-type Eye Conditions | Astellas Institute for Regenerative Medicine | Phase 1 | Recruiting | Stargardt Disease, Stargardt Macular Dystrophy, Stargardt-like Macular Dystrophy | 30 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07734064) |

## Sites with the most of these trials

Sites as the records name them, organizations only.

| Site | City | Trials |
| --- | --- | --- |
| University of Mississippi Medical Center | Jackson | 102 |
| Baptist Memorial Hospital and Cancer Center-Oxford | Oxford | 44 |
| Baptist Memorial Hospital and Cancer Center-Desoto | Southhaven | 44 |
| Baptist Cancer Center-Grenada | Grenada | 40 |
| Baptist Memorial Hospital and Cancer Center-Union County | New Albany | 40 |
| Baptist Memorial Hospital and Cancer Center-Golden Triangle | Columbus | 39 |
| Hattiesburg Clinic | Hattiesburg | 12 |
| Gulfport Memorial Hospital | Gulfport | 10 |
| Precise Research Centers | Flowood | 10 |
| Hattiesburg Clinic Hematology/Oncology | Hattiesburg | 7 |
| Jackson Heart Clinic | Jackson | 7 |
| SKY Integrative Medical Center/SKYCRNG | Ridgeland | 6 |
| Singing River Hospital | Pascagoula | 5 |
| North Mississippi Medical Center | Tupelo | 5 |
| Southern Specialty Research | Flowood | 5 |
| University of Mississippi | Jackson | 5 |
| Mississippi Baptist Medical Center | Jackson | 4 |
| Memorial Hospital at Gulfport | Gulfport | 4 |
| Mississippi Retina Associates | Madison | 4 |
| Olive Branch Family Medical Center | Olive Branch | 4 |
| University of Mississippi Medical Center - Children's of Mississippi | Jackson | 3 |
| Deep Blue Retina Clinical Research PLLC | Southaven | 3 |
| North Mississippi Hematology and Oncology Associates | Tupelo | 3 |
| Hattiesburg Hematology and Oncology Clinic | Hattiesburg | 3 |
| Mississippi Center for Advanced Medicine | Madison | 2 |

## By phase

| Phase | Trials |
| --- | --- |
| Phase 1 | 5 |
| Phase 1/2 | 5 |
| Phase 2 | 72 |
| Phase 2/3 | 11 |
| Phase 3 | 184 |
| Phase 4 | 15 |
| Not applicable | 61 |
| Observational | 40 |

## Conditions

| Condition group | Trials |
| --- | --- |
| Carcinoma, Non-Small-Cell Lung | 22 |
| Obesity | 18 |
| Lung Neoplasms | 16 |
| Overweight | 13 |
| Cardiovascular Diseases | 11 |
| Diabetes Mellitus, Type 2 | 10 |
| Breast Neoplasms | 10 |
| Neoplasms | 9 |
| Heart Failure | 8 |
| Prostatic Neoplasms | 8 |
| Neoplasm Metastasis | 8 |
| Hypertension | 7 |
| Leukemia, Myeloid, Acute | 7 |
| Coronary Artery Disease | 7 |
| Carcinoma | 6 |
| Migraine Disorders | 6 |
| Macular Degeneration | 6 |
| Colorectal Neoplasms | 6 |
| Colitis, Ulcerative | 6 |
| Anemia, Sickle Cell | 6 |
| Ovarian Neoplasms | 6 |
| Leukemia, Lymphocytic, Chronic, B-Cell | 5 |
| Attention Deficit Disorder with Hyperactivity | 5 |
| Colonic Neoplasms | 5 |
| Alzheimer Disease | 5 |

## Sponsors with the most

| Sponsor | Trials |
| --- | --- |
| National Cancer Institute (NCI) | 27 |
| SWOG Cancer Research Network | 19 |
| Children's Oncology Group | 18 |
| [Pfizer](https://specstream.ai/data/clinical-trials/company/pfizer) | 13 |
| [Merck Sharp & Dohme LLC](https://specstream.ai/data/clinical-trials/company/merck-sharp-and-dohme-llc) | 11 |
| [Eli Lilly and Company](https://specstream.ai/data/clinical-trials/company/eli-lilly-and-company) | 11 |
| [AbbVie](https://specstream.ai/data/clinical-trials/company/abbvie) | 10 |
| University of Mississippi Medical Center | 10 |
| Alliance for Clinical Trials in Oncology | 10 |
| [Boehringer Ingelheim](https://specstream.ai/data/clinical-trials/company/boehringer-ingelheim) | 9 |
| [Bristol-Myers Squibb](https://specstream.ai/data/clinical-trials/company/bristol-myers-squibb) | 8 |
| [AstraZeneca](https://specstream.ai/data/clinical-trials/company/astrazeneca) | 8 |
| NRG Oncology | 7 |
| [Janssen Research & Development, LLC](https://specstream.ai/data/clinical-trials/company/janssen-research-and-development-llc) | 7 |
| [Hoffmann-La Roche](https://specstream.ai/data/clinical-trials/company/hoffmann-la-roche) | 7 |
| Duke University | 5 |
| [Regeneron Pharmaceuticals](https://specstream.ai/data/clinical-trials/company/regeneron-pharmaceuticals) | 5 |
| [Amgen](https://specstream.ai/data/clinical-trials/company/amgen) | 4 |
| NICHD Neonatal Research Network | 4 |
| ECOG-ACRIN Cancer Research Group | 4 |
| [Novartis Pharmaceuticals](https://specstream.ai/data/clinical-trials/company/novartis-pharmaceuticals) | 4 |
| Wake Forest University Health Sciences | 3 |
| [Karuna Therapeutics, Inc., a Bristol Myers Squibb company](https://specstream.ai/data/clinical-trials/company/karuna-therapeutics-inc-a-bristol-myers-squibb-company) | 3 |
| [Novo Nordisk A/S](https://specstream.ai/data/clinical-trials/company/novo-nordisk-a-s) | 3 |
| Mayo Clinic | 3 |

## Where the register publishes

- [ClinicalTrials.gov](https://clinicaltrials.gov/)
- [ClinicalTrials.gov API](https://clinicaltrials.gov/data-api/api)

Source: [ClinicalTrials.gov API v2 (U.S. National Library of Medicine)](https://clinicaltrials.gov/data-api/api). U.S. government data; ClinicalTrials.gov terms of use. Studies are as their sponsors registered them on ClinicalTrials.gov, read through its API. Recruiting means the record's overall status is recruiting or not yet recruiting. Condition groups are the MeSH terms ClinicalTrials.gov assigns; a condition page also counts the narrower terms that name it, as the register's own search does (triple negative breast neoplasms are breast neoplasms). Sites are shown as organizations only; no investigator or contact is read or shown.

Free to quote with credit and a link. Copying in bulk needs a [data licence](https://specstream.ai/data/licence).

## Business lists in Mississippi

- [Banks and credit unions in Mississippi, United States](https://specstream.ai/data/businesses/banks-and-credit-unions/mississippi-united-states)
- [Water utilities in Mississippi, United States](https://specstream.ai/data/businesses/water-utilities/mississippi-united-states)
- [Sports bars in Mississippi, United States](https://specstream.ai/data/businesses/sports-bars/mississippi-united-states)
- [Printing companies in Mississippi, United States](https://specstream.ai/data/businesses/printing-companies/mississippi-united-states)
- [Naturopathic clinics in Mississippi, United States](https://specstream.ai/data/businesses/naturopathic-clinics/mississippi-united-states)
- [Land surveyors in Mississippi, United States](https://specstream.ai/data/businesses/land-surveyors/mississippi-united-states)
